News headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stemline Therapeutics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6715498492624 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research firms have recently commented on STML. ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. HC Wainwright set a $34.00 target price on Stemline Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $33.40.
Shares of Stemline Therapeutics (NASDAQ STML) opened at $15.55 on Monday. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $15.60.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
What are top analysts saying about Stemline Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc. and related companies.